The global Molecular Biology Enzymes And Kits & Reagents market size was valued at USD 5.77 billion in 2016 and is expected to witness a CAGR of 19.0% during the forecast period. Increase in research activities by end users has been one of the key factors responsible for the surge in demand for molecular biology enzymes, kits, and reagents.
The rising prevalence of genetic disorders is anticipated to propel the molecular diagnostics market. Molecular biology enzymes, kits, and reagents are used in Polymerase Chain Reaction (PCR) and epigenetics in molecular diagnostics. The market is further propelled by increased incidence of genetic disorders amongst the geriatric population.
U.S. molecular biology enzymes and kits & reagents market by product, 2014 - 2025 ($ billion)
Technological advancements in molecular biology enzymes, kits, and reagents are one of the factors contributing to growth. Manufacturers continuously develop advanced products with an objective to increase their share. These advanced products aim to ease research processes by offering enhanced efficiency and higher precision. For instance, in June 2015, Thermo Fisher Scientific, Inc. (U.S.) launched the new SMART Digest Kit, which was designed for biopharmaceutical and proteomic applications. The kit was designed to generate high-quality data with a significantly reduced sample preparation time compared to traditional in-solution digestion methods.
Increasing investments by pharmaceutical & biotechnology companies in research activities, increased availability of funds for academic & research institutions, and provision of reimbursement for molecular diagnostics are other significant factors propelling growth.
Genetic information of an individual is highly confidential, hence cannot be shared. Genome sequencing aids in identification and treatment of various diseases & disorders. Globally, there are no effective tools to secure the genetic information of an individual. Genetic information is accessible to doctors and insurance companies. This information is stored in a cloud database and can be used by researchers across the globe. Thus, lack of high-end technology to store genetic information is likely to restrain growth in the coming years.
The kits and reagents segment dominated in terms of revenue share in 2016. Low costs of kits & reagents and their repeated use in everyday processes are the major factors driving this market. This segment is also expected to grow at the fastest rate during the forecast period.
The kits and reagents market is characterized by the presence of a large number of local and international manufacturers. The cost involved in the manufacturing of reagents is significantly low, which further aids the manufacturers in developing advanced products. Moreover, these products are frequently used in various research processes, which further augments their demand.
The kits and reagents market is also expected to grow at the fastest rate during the forecast period. The ready availability of complete kits is one of the major factors contributing to this growth rate. Furthermore, growing preference and adoption of molecular diagnostics is expected to propel growth.
The enzymes market in the recent years has witnessed a significant growth owing to the availability of new thermostable enzymes that can be used and stored at varying temperatures. In November 2014, New England Biolabs, Inc. (U.S.) launched WarmStart RTx Reverse Transcriptase, a thermostable reverse transcriptase, designed specifically for detection of nucleic acid. The enzyme is reversibly inhibited at room temperature and can be activated at 40°C. This reversible WarmStart functionality enables researchers to set up reactions at room temperature with no background reverse transcriptase activity.
Based on application, the market is segmented into PCR, sequencing, epigenetics, cloning, restriction digestion, and synthetic biology. The PCR segment held the largest share of the market, by application in 2016.
The largest share held by this segment can be attributed to increasing demand for molecular diagnostics and detection of various diseases. Furthermore, the manufacturers of PCR equipment and consumables are witnessing influx of public & private funding globally. For instance, in November 2016, Belgian Bioinformatics firm UgenTec NV raised around USD 2.3 million from various investors including BNP Paribas Fortis SA/NV (Belgium). These funds are likely to be used for development of PCR for data analysis and processing.
Global molecular biology enzymes and kits & reagents market by application, 2016 (%)
The sequencing application segment is estimated to grow at the fastest rate during the forecast period. In the recent years, hospitals in developed or developing countries are implementing sequencing-based medical treatment. Furthermore, sequencing is also being used in cancer diagnosis, therapy, and treatment in collaboration with bioinformatics. In addition, the decreasing cost of sequencing is expected to increase the demand for sequencing during the forecast period.
Epigenetics is used during drug development and discovery process of cancer drugs. In the recent years, many countries across the globe are witnessing growth in the biopharmaceutical and biotechnology industry. For instance, according to the India Brand Equity Foundation, the biopharmaceutical industry is India was worth USD 11 million in 2016 and is estimated to reach USD 11.6 billion by 2017.
Synthetic biology is a new method wherein engineering principles are combined with biology to make new biological products. The growth of the synthetic biology market can be attributed to decreasing cost of DNA sequencing and increasing demand for vaccines, drugs, genetically modified crops, & biofuels.
In 2016, North America held the largest revenue share of the molecular biology enzymes, kits, and reagents market. Factors contributing to growth include increasing research activities in the field of genomics, expanding pharmaceutical industry in the U.S., and various awareness activities being held in Canada. However, regulatory laws for human cloning are likely to restrain growth during the forecast period.
Rise in government initiatives in the genomics applications backed by personalized medicine initiative is expected to result in lucrative growth over the forecast period. In addition to this, an increasing number of research activities are being witnessed in genomics in this region over the past years.
Global molecular biology enzymes and kits & reagents market, by region, 2016 (%)
Asia Pacific is expected to grow at the fastest CAGR of over 19.8% during the forecast period due to growing geriatric population in Japan & China, expanding pharmaceutical & biotechnology industry in India & China, increased initiatives by governments of India, China, & Japan to boost the biotechnology industry, and growing focus by key manufacturers on expansion activities in these countries.
Europe held the second largest share of the molecular biology enzymes, kits, and reagents market. This share can be attributed to incessant research funding in the UK, growing biotechnology industry in Germany, and investments in genomic sequencing backed by conferences for creating awareness & enhancing skills of researchers.
Some of the key participants include Thermo Fisher Scientific, Inc.; Merck KGaA; Illumina, Inc.; QIAGEN; New England Biolabs; Agilent Technologies; Takara Bio, Inc.; Promega Corporation; F. Hoffmann-La Roche Ltd; and Lucigen Corporation.
Major players such as Thermo Fisher Scientific, Inc.; Agilent Technologies; and Illumina, Inc. aimed at increasing their share through incessant product launches. For instance, in December 2016, New England Biolabs launched Luna Universal qPCR & RT-qPCR kits for DNA or RNA quantitation from different samples and target types. The kits are formulated with reference dye and a blue dye for easy quantitation. New product launches help players enhance their share in the highly competitive molecular biology enzymes, kits, and reagents market.
In addition, other key participants like Merck KGaA and QIAGEN acquired other players to expand their product portfolio and thereby increase their share. For instance, in January 2015, QIAGEN acquired Enzyme Solutions unit of Enzymatics Inc. (U.S.), a manufacturer of Next-Generation Sequencing (NGS) reagents and solutions. With this acquisition, the company significantly expanded its NGS product portfolio.
The players in molecular biology enzymes, kits, and reagents market also implemented strategies like geographic and manufacturing capacity expansions. For instance, in August 2015, TAKARA BIO, INC. opened a new facility at Kusatsu, Shiga. The company’s headquarters has also been relocated to this new facility. This relocation was expected to enhance the efficiency of R&D activities and provide genetic analysis services.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global Molecular Biology Enzymes And Kits & Reagents market on the basis of product, application, end user, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Kits and Reagents
Application Outlook (Revenue, USD Million, 2014 - 2025)
End User Outlook (Revenue, USD Million, 2014 - 2025)
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Hospitals and Diagnostic Centers
Other End Users
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East and Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.